Sugi Predict

Sugi Predict / Compounds / SCHEMBL1762291

SCHEMBL1762291

SCHEMBL1762291

O=C(Cl)c1ccc(S(=O)(=O)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.47
▸ F2 P00734 2/20 0.41
▸ TMPRSS4 Q9NRS4 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KMT2A Q03164 1/20 0.39
▸ CA2 P00918 7/20 0.39
▸ CA1 P00915 5/20 0.39
▸ CA9 Q16790 4/20 0.39
▸ CA12 O43570 3/20 0.39
▸ CA14 Q9ULX7 3/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ FLT1 P17948 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL724893 0.81 ALDH1A1 (0.50) ALDH1A1TSHRKMT2A
SCHEMBL35155 0.79 ALDH1A1 (0.48) ALDH1A1KMT2ACA2CA1CA9
SCHEMBL7825255 0.79 CA2 (0.61) ALDH1A1F2TP53TSHRKMT2A
SCHEMBL8747696 0.79 LMNA (0.52) ALDH1A1CYP2D6TSHRKMT2ACA2
SCHEMBL497483 0.77 CA2 (0.65) CA2CA1CA9CA12CA14
SCHEMBL18633389 0.77 CA2 (0.65) ALDH1A1F2TMPRSS4TP53CYP1A2
SCHEMBL28216095 0.77 MAPT (0.52) ALDH1A1KMT2ACA2CA1CA9
SCHEMBL599583 0.77 ENPP2 (0.54) MAOB
SCHEMBL9659082 0.77 LMNA (0.50) ALDH1A1CYP2D6TSHRKMT2ACA2
SCHEMBL9659087 0.77 ALDH1A1 (0.47) ALDH1A1KMT2ACA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
EP-4282857-B1 RADIOACTIVE HALOGEN-LABELED PRECURSOR COMPOUND INST OF SCIENCE TOKYO (JP) 2026-04-15 — — EP disclosed
US-20250296912-A1 AFFINITY ILLUDOFULVENE CONJUGATES Illudent, Inc. (US) 2025-09-25 — — US disclosed
US-20250283138-A1 BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-09-11 — — US disclosed
US-20250241872-A1 AFFINITY MEDICANT CONJUGATE Illudent, Inc. (US) 2025-07-31 — — US disclosed
US-12280021-B2 Affinity medicant conjugate AF CHEMICALS, LLC (US) 2025-04-22 — — US disclosed
US-12269793-B2 Affinity illudofulvene conjugates AF CHEMICALS, LLC (US) 2025-04-08 — — US disclosed
EP-4257186-B1 AFFINITY MEDICANT CONJUGATES AF CHEMICALS LLC (US) 2024-12-04 — — EP disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
EP-1064273-A2 1,3,4-THIADIAZOLES USEFUL FOR THE TREATMENT OF CMV INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2001-01-03 — — EP disclosed
US-6161544-A Methods for accelerated orthokeratology KERATOFORM, INC. (US) 2000-12-19 — — US disclosed
US-6150385-A VIRICIDE WITH ACTIVITY AGAINST CYTOMEGALO VIRUS (CMV), HERPES VIRUS INCLUDING VARICELLA ZOSTER VIRUS, THE EPSTEIN-BARR VIRUS, THE HERPES SIMPLEX VIRUS, AND THE HUMAN HERPES VIRUS TYPE 8 (HHV-8) PHARMACIA & UPJOHN COMPANY (US) 2000-11-21 — — US disclosed
EP-1051655-A1 METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY Ista Pharmaceuticals, Inc. (US) 2000-11-15 — — EP disclosed
WO-2000035909-A1 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 — — WO disclosed
WO-1999047507-A2 1,3,4-THIADIAZOLES USEFUL FOR THE TREATMENT OF CMV INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1999-09-23 — — WO disclosed
WO-1999039238-A1 METHODS AND APPARATUS FOR ACCELERATED ORTHOKERATOLOGY KERATOFORM, INC. (US) 1999-08-05 — — WO disclosed
US-5391723-A Oligonucleotide conjugates NEORX CORPORATION (US) 1995-02-21 — — US disclosed
US-4492683-A Method for inhibiting the growth of fungi with phenyl glycine compounds BUFFALO COLOR CORPORATION (US) 1985-01-08 — — US disclosed
US-4069224-A N-(PYRIDYLALKYL)BENZAMIDES, IMPROVE PRODUCTION OF PROSTAGLANDINS IN MAMMALS THE UPJOHN COMPANY (US) 1978-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296912-A1 AFFINITY ILLUDOFULVENE CONJUGATES OGFR, TNFSF11, FCER2 ALDH1A1 4400/4885F2 745/4885TMPRSS4 527/4885
US-12280021-B2 Affinity medicant conjugate FCER2, HDGF, FCGR2A ALDH1A1 3966/4885F2 926/4885TMPRSS4 1871/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 1816/4885F2 3533/4885TMPRSS4 3278/4885
US-20250283138-A1 BIOREACTIVE COMPOUNDS AND METHODS OF USE THEREOF BCAT2, BCAT1, AADAT ALDH1A1 495/4885F2 1774/4885TMPRSS4 1512/4885
US-12269793-B2 Affinity illudofulvene conjugates OGFR, TNFSF11, FCER2 ALDH1A1 4400/4885F2 745/4885TMPRSS4 527/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS ALDH1A1 1957/4885F2 2344/4885TMPRSS4 3208/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2681/4885F2 2972/4885TMPRSS4 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.